ClinicalTrials.gg
CompletedNCT04644237DESTINY-LUNG02Updated Nov 21, 2025Results posted

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Trastuzumab deruxtecan in Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo. Completed at 50 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 9 under way, 2 of them phase 3. trastuzumab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
7th of 12
152 · median 167
Started
2021
with 2 others
Phase 2
7 of 12
2 open now
Registered
4th of 12
by date
Lead sponsor
4 of 12
Daiichi Sankyo

Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one regimen of prior anticancer therapy (second line or later) that must have contained a platinum-based chemotherapy drug.

Read the detailed description

This randomized, two-arm, phase 2, multicenter study will evaluate the safety and efficacy of 5.4 mg/kg and 6.4 mg/kg trastuzumab deruxtecan administered every 3 weeks (Q3W) in participants with HER2-mutated metastatic NSCLC. Each participant is expected to receive approximately 14 months of trastuzumab deruxtecan treatment. The primary endpoint of the study will be confirmed objective response rate (blinded independent central review). Secondary endpoints will include, but not limited to, disease control rate, duration of response, progression-free survival, objective response rate (investigator), overall survival, and safety.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Non-small Cell Lung Cancer
  • Trastuzumab Deruxtecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Men or women ≥18 years, follow local regulatory requirements if the legal age of the consent for study participation is >18 years
  • documented NSCLC with a known activating mutation. Note: A HER2 mutation documented only from a liquid samples cannot be used for enrollment.
  • Had previous treatment including platinum therapy in the metastatic/locally advanced setting and not amenable to curative surgery or radiation. Participant must have progressed during or after the last treatment regimen or discontinued because of unacceptable toxicity.
  • Presence of at least 1 confirmed by the blinded Independent Central Review based on version 1.1
  • Willing and able to provide an archival tumor tissue sample. A fresh biopsy is required if an archival tumor tissue sample cannot be supplied. Resection and core needle biopsy are acceptable. Fine needle aspirates or cell block are not acceptable.
  • performance status 0 to 1
  • ≥ 50% within 28 days before randomization Resection and core needle biopsy are acceptable - Adequate organ function as specified in protocol within 14 days before randomization
  • Adequate treatment before randomization
  • Participants of reproductive/ agree to use a highly effective form of (or avoid intercourse) during study period and up to 7 months (females) and 4 months (males) after last study dose
  • Males should not freeze or donate sperm throughout the study period up to at least 4 months after last study dose; females should not donate or retrieve ova for their own use throughout the study period and up to at least 7 months after last study dose
  • 3 months or more

Exclusion criteria

Exclusion Criteria:

  • Known driver mutation in the epidermal growth factor receptor (EGFR), BRAF, or MET exon 14 gene or a known anaplastic lymphoma kinase (ALK), ROS1, RET, or NTRK fusion
  • Medical history of myocardial infarction within 6 months before randomization, symptomatic congestive heart failure (CHF) ( Class II to IV). Participants with troponin levels above at screening (as defined by the manufacturer) and without any myocardial infarction (MI)-related symptoms should have a cardiologic consultation before randomization to rule out MI
  • interval (QTcF) prolongation > 470 msec (females) or >450 msec (males) based on average of the triplicate12-lead at screening
  • History of non-infectious interstitial lung disease (ILD)/pneumonitis that required , current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • Spinal cord compression or clinically active central nervous system , defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
  • Multiple primary within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
  • History of severe reactions to either the drug substances or inactive ingredients in the drug product
  • History of severe hypersensitivity reactions to other monoclonal antibodies
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Substance abuse or any other medical conditions such as cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the participant's participation in the clinical study or evaluation of the clinical study results
  • Known (HIV) infection
  • Known active, clinically relevant liver disease (eg, active , or active ) such as those with serologic evidence of viral infection within 28 days of Cycle 1, Day 1
  • Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline
  • Pregnant, breastfeeding, or planning to become pregnant
  • Otherwise considered inappropriate for the study by the Investigator
  • Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg. pulmonary emboli within three months of the study randomization, severe asthma, severe , restrictive lung disease, pleural effusion, etc.)
  • Any , connective tissue or inflammatory disorders (e.g., Rheumatoid arthritis, Sjogren's, sarcoidosis etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening
  • Prior complete pneumonectomy
  • Had prior treatment with any agent, including an antibody drug conjugate (ADC), containing a chemotherapeutic agent targeting topoisomerase I
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Trastuzumab deruxtecan 6.4 mg/kg

    Participants will be randomized to receive trastuzumab deruxtecan 6.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).

    Drug: Trastuzumab deruxtecan

  • Experimental
    Trastuzumab deruxtecan 5.4 mg/kg

    Participants will be randomized to receive trastuzumab deruxtecan 5.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).

    Drug: Trastuzumab deruxtecan

Interventions

  • Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

    Confirmed objective response rate (ORR), defined as the proportion of participants with complete response (CR) or partial response (PR), was assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: 9 months after the last participant is randomized to data cut off, up to approximately 21 months

Secondary outcomes

  1. Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors

    Confirmed objective response rate (ORR), defined as the percentage of participants with complete response (CR) or partial response (PR), will be assessed by the Investigator based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: 9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

  2. Duration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

    Duration of response (DoR) is defined as the time from the initial response (complete response \[CR\] or partial response \[PR\]) until documented tumor progression or death from any cause. DoR is only defined for participants who achieved confirmed CR or PR. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: 9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

  3. Disease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

    Disease control rate (DCR) is the sum of complete response (CR), partial response (PR), and stable disease (SD) rates. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.

    Time frame: 9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

  4. Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

    Progression-free survival (PFS) is defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on blinded independent central review (BICR) and investigator assessment.

    Time frame: 9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

  5. Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors

    Overall survival (OS) is defined as the time from date of randomization until death from any cause.

    Time frame: 9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

  6. The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors

    Time frame: 9 months after the last participant is randomized or later to data cut off, up to approximately 35 months

  7. Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a

    Time frame: Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)

  8. Pharmacokinetic Parameter Minimum Observed Concentration (Ctrough) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a

    Time frame: Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)

  9. Pharmacokinetic Parameter Area Under the Serum Concentration-Time Curve (AUC) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a

    Time frame: Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)

  10. Number of Participants With Anti-Drug Antibodies (ADA) Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors

    Time frame: Pre-dose on Day 1 of Cycles 1, 2 and 4, and then every 4 cycles (each cycle is 21 days), up to Cycle 28 and End of Treatment.

  11. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores

    The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms. The QLQ-LC13 is a 13-item questionnaire designed to assess lung cancer-related symptoms and treatment side effects. The scales ranges from 1=not at all to 4=very much. The summation of scores range from 0 to 100, where higher scores represent increasing symptoms levels. scales.

    Time frame: At baseline and at end of treatment 40-day follow-up visit

  12. Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores

    The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.

    Time frame: At baseline and at end of treatment 40-day follow-up visit

07

Results

Posted Jan 30, 2024

Participant flow

A total of 152 participants were enrolled and treated at clinic centers in North America, Europe, and Asia-Pacific.

Participant flow — Overall Study
MilestoneTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Started10250
Completed00
Not completed10250
Withdrew: Death42
Withdrew: Adverse event1819
Withdrew: Progressive disease6123
Withdrew: Clinical progression41
Withdrew: Withdrawal by subject42
Withdrew: Physician decision40
Withdrew: Other63
Withdrew: Randomized but not treated10

Outcome measures

PrimaryPercentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

Confirmed objective response rate (ORR), defined as the proportion of participants with complete response (CR) or partial response (PR), was assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
9 months after the last participant is randomized to data cut off, up to approximately 21 months
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
percentage of participantsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer50.0 (39.9 to 60.1)56.0 (41.3 to 70.0)
SecondaryPercentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors

Confirmed objective response rate (ORR), defined as the percentage of participants with complete response (CR) or partial response (PR), will be assessed by the Investigator based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors
Percentage of participantsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors46.1 (36.2 to 56.2)56.0 (41.3 to 70.0)
SecondaryDuration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

Duration of response (DoR) is defined as the time from the initial response (complete response \[CR\] or partial response \[PR\]) until documented tumor progression or death from any cause. DoR is only defined for participants who achieved confirmed CR or PR. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
Reported as:
Median · months
Duration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
monthsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Duration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer11.1 (8.3 to 15.5)12.9 (6.9 to 15.4)
SecondaryDisease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

Disease control rate (DCR) is the sum of complete response (CR), partial response (PR), and stable disease (SD) rates. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.

Time frame:
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
Reported as:
Number · Percentage of participants
Disease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
Percentage of participantsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Disease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer90.2 (82.7 to 95.2)88.0 (75.7 to 95.5)
SecondaryProgression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer

Progression-free survival (PFS) is defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on blinded independent central review (BICR) and investigator assessment.

Time frame:
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
Reported as:
Median · months
Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
monthsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer9.7 (8.2 to 11.3)9.5 (6.5 to 15.1)
SecondaryOverall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors

Overall survival (OS) is defined as the time from date of randomization until death from any cause.

Time frame:
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
Reported as:
Median · months
Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors
monthsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors19.0 (14.7 to NA)17.9 (13.8 to NA)
SecondaryThe Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors
Time frame:
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
Reported as:
Count of participants · Participants
The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors
ParticipantsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors10150
SecondaryPharmacokinetic Parameter Maximum Serum Concentration (Cmax) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a
Time frame:
Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)
Reported as:
Mean · µg/mL
Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a
µg/mLTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Trastuzumab Deruxtecan148 ± 69.5196 ± 184
Total Anti-HER2 Antibody138 ± 57.8179 ± 194
DXd (Metabolite Active Metabolite MAAA-1181a).015 ± .007.018 ± .008
SecondaryPharmacokinetic Parameter Minimum Observed Concentration (Ctrough) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a
Time frame:
Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)
Reported as:
Mean · µg/mL
Pharmacokinetic Parameter Minimum Observed Concentration (Ctrough) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a
µg/mLTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Trastuzumab Deruxtecan5.47 ± 11.15.84 ± 3.48
Total Anti-HER2 Antibody6.39 ± 10.77.16 ± 5.00
DXd (Metabolite Active Metabolite MAAA-1181a).0003 ± .0003.0003 ± .0002
SecondaryPharmacokinetic Parameter Area Under the Serum Concentration-Time Curve (AUC) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a
Time frame:
Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)
Reported as:
Mean · µg × d/mL
Pharmacokinetic Parameter Area Under the Serum Concentration-Time Curve (AUC) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a
µg × d/mLTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Trastuzumab Deruxtecan658 ± 185793 ± 210
Total Anti-HER2 Antibody697 ± 208829 ± 261
DXd (Metabolite Active Metabolite MAAA-1181a).050 ± .022.059 ± .017
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA) Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors
Time frame:
Pre-dose on Day 1 of Cycles 1, 2 and 4, and then every 4 cycles (each cycle is 21 days), up to Cycle 28 and End of Treatment.
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA) Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors
ParticipantsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Number of Participants With Anti-Drug Antibodies (ADA) Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors21
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores

The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms. The QLQ-LC13 is a 13-item questionnaire designed to assess lung cancer-related symptoms and treatment side effects. The scales ranges from 1=not at all to 4=very much. The summation of scores range from 0 to 100, where higher scores represent increasing symptoms levels. scales.

Time frame:
At baseline and at end of treatment 40-day follow-up visit
Reported as:
Mean · score on scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores
score on scaleTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
QLQ-C30: Change from Baseline 40-Day Follow-up-1.11 ± 17.78015.63 ± 31.947
QLQ-LC13: Change from Baseline 40-Day Follow-up-2.38 ± 24.335-29.17 ± 27.817
SecondaryTime to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores

The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.

Time frame:
At baseline and at end of treatment 40-day follow-up visit
Reported as:
Median · months
Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores
monthsTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores8.6 (4.9 to 11.4)9.3 (2.5 to NA)

Adverse events

Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up to approximately 35 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Deruxtecan 5.4 mg/kg52/102 (51%)42/101 (41.6%)101/101 (100%)
Trastuzumab Deruxtecan 6.4 mg/kg24/50 (48%)26/50 (52%)50/50 (100%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
PneumoniaInfections and infestations2/1013/50
AnaemiaBlood and lymphatic system disorders0/1012/50
FatigueGeneral disorders1/1012/50
General physical health deteriorationGeneral disorders1/1012/50
MalaiseGeneral disorders0/1012/50
Neutrophil count decreasedInvestigations1/1012/50
Platelet count decreasedInvestigations1/1012/50
DehydrationMetabolism and nutrition disorders0/1012/50
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/1012/50
PneumonitisRespiratory, thoracic and mediastinal disorders2/1012/50
Most frequent other events
Showing 10 of 50
Most frequent other events
EventTrastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kg
NauseaGastrointestinal disorders69/10141/50
Decreased appetiteMetabolism and nutrition disorders41/10125/50
AnaemiaBlood and lymphatic system disorders41/10124/50
VomitingGastrointestinal disorders31/10122/50
Neutrophil count decreasedInvestigations32/10120/50
ConstipationGastrointestinal disorders38/10117/50
DiarrhoeaGastrointestinal disorders25/10118/50
AlopeciaSkin and subcutaneous tissue disorders22/10117/50
White blood cell count decreasedInfections and infestations26/10116/50
Platelet count decreasedInvestigations26/10116/50

Baseline characteristics

The baseline demographic characteristics were assessed in the Full Analysis Set.

Age, Categorical
Age, Categorical(Participants)Trastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kgTotal
<=18 years000
Between 18 and 65 years623597
>=65 years401555
Age, Continuous
Age, Continuous(years)Trastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kgTotal
Mean59.8 ± 11.5959.5 ± 12.1459.7 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kgTotal
Female653499
Male371653
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab Deruxtecan 5.4 mg/kgTrastuzumab Deruxtecan 6.4 mg/kgTotal
American Indian or Alaska Native000
Asian653196
Native Hawaiian or Other Pacific Islander000
Black or African American022
White23528
More than one race000
Unknown or Not Reported141226
08

Study locations

50 sites
  • University of Colorado Denver - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40241, United States
  • Massachusetts General Hospital (MGH) - Hematology/Oncology
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Cancer Institute/Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • University of Michigan
    Detroit, Michigan 48202, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Virgina Cancer Specialists
    Fairfax, Virginia 22031, United States
  • St John of God Subiaco Hospital
    Subiaco, 6008, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • University Health Network
    Toronto, M5G0A3, Canada
  • Centre Leon Berard
    Lyon, 69008, France
  • Assistance Publique Hopitaux de Marseille AP-HM, Hopital NORD
    Marseille, 13015, France
  • Hopital Pontchaillou
    Rennes, 35000, France
  • CHU Nantes
    Saint-Herblain, 44800, France
  • CHU toulouse - hôpital Larrey
    Toulouse, 31059, France
  • Gustav Roussy
    Villejuif, 94800, France
  • Ospedale San Luca
    Lucca, 55100, Italy
  • IRCCS Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • SC Oncologia, AOU Policlinico Modena
    Modena, 41124, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Strutturadi Oncologia
    Naples, 80131, Italy
  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Humanitas Cancer Center Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Aichi Cancer Center Hospital
    Chikusa, 464-8681, Japan
  • National Cancer Central Hospital
    Chūōku, 104-0045, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 11111, Japan
  • National Cancer Center Hospital East
    Kashiwa, 277-0882, Japan
  • Okayama University Hospital
    Okayama, 700-8558, Japan
  • Kindai University Hospital
    Ōsaka-sayama, 589-8511, Japan
  • Netherlands Cancer Institute
    Amsterdam, 1066CX, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • Seoul National University Bundang Hospital
    Seongnam, 463-707, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center
    Seoul, 3080, South Korea
  • Samsung Medical Center
    Seoul, 6351, South Korea
  • Chungbuk National University Hospital
    Taebuk, 28644, South Korea
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08023, Spain
  • Clinica Universidad de Navarra
    Madrid, 28027, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Clinica Univ. de Navarra - P
    Pamplona, 31008, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
  • Chung Shan Medical University Hospital
    Taichung, 40705, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital NCKUH
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Chang Gung Memorial Hospital CGMH - LinKou Branch
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Janne PA. Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: a plain language summary of the DESTINY-Lung02 study. Future Oncol. 2026 Mar;22(6):659-670. doi: 10.1080/14796694.2025.2598216. Epub 2026 Feb 14. PubMed 41689406 ↗
  • Janne PA, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit E, Johannes de Langen A, Perol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Pereira K, Cheng FC, Taguchi A, Cheng Y, Dunton K, Ali A, Goto K. Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC. J Thorac Oncol. 2025 Dec;20(12):1814-1828. doi: 10.1016/j.jtho.2025.07.129. Epub 2025 Jul 30. PubMed 40749900 ↗
  • Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, Perol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Kuo CH, Yang JC, Pereira K, Cheng FC, Taguchi A, Cheng Y, Feng W, Tsuchihashi Z, Janne PA. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11. PubMed 37694347 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Dec 2022, 21 months.

Results were first posted in Jan 2024, 1 year 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2020
First posted
Nov 25, 2020
StartActual
Mar 19, 2021
Primary completionActual
Dec 23, 2022
CompletionActual
Aug 23, 2024
Results first posted
Jan 30, 2024
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04644237
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Mar 19, 2021
Primary completion
Dec 23, 2022
Completion
Aug 23, 2024
Results posted
Jan 30, 2024
Last update
Nov 21, 2025

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion